Suppr超能文献

以肠道微生物群为靶点治疗原发性胆汁性胆管炎:从实验台到临床应用

Targeting Gut Microbiota for the Treatment of Primary Biliary Cholangitis: From Bench to Bedside.

作者信息

Zhang Li, Yang Ling, Chu Huikuan

机构信息

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

出版信息

J Clin Transl Hepatol. 2023 Aug 28;11(4):958-966. doi: 10.14218/JCTH.2022.00408. Epub 2023 Mar 1.

Abstract

Primary biliary cholangitis (PBC) is a complex cholestatic liver disease with an unresolved etiology. The gut microbiota is composed of a dynamic community of bacteria, archaea, fungi, and viruses that have a key role in physiological processes related to nutrition, immunity, and host defense responses. A number of recent studies found that the composition of the gut microbiota of PBC patients was significantly altered, and reported that gut dysbiosis might arise during PBC development because of the close interactions of the liver and the gut. In light of the growing interest in this topic, the focus of this review is to characterize PBC gut microbiota alterations, the correlation between PBC pathology and the gut microbiota, and prospective therapies that target the altered gut microbiota, such as probiotics and fecal microbiota transplantation.

摘要

原发性胆汁性胆管炎(PBC)是一种病因尚未明确的复杂胆汁淤积性肝病。肠道微生物群由细菌、古菌、真菌和病毒组成的动态群落构成,它们在与营养、免疫和宿主防御反应相关的生理过程中起关键作用。最近的一些研究发现,PBC患者的肠道微生物群组成发生了显著改变,并报告称由于肝脏和肠道的密切相互作用,肠道生态失调可能在PBC发展过程中出现。鉴于对该主题的兴趣日益浓厚,本综述的重点是描述PBC肠道微生物群的改变、PBC病理学与肠道微生物群之间的相关性,以及针对改变的肠道微生物群的前瞻性治疗方法,如益生菌和粪便微生物群移植。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465b/10318297/17d2be01e139/JCTH-11-958-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验